April 18, 2024

Alpha 1 Lung Disease Market is trending towards Gene Therapy by 2028 and beyond

The Alpha 1 Lung Disease Market comprises treatments and drugs that help in managing Alpha 1 Lung Disease symptoms. Alpha 1 Lung Disease is a genetic condition which causes liver and lung problems primarily due to deficiency of Alpha 1 antitrypsin (AAT), a protein that protects the lungs. Some advantages of Alpha 1 Lung Disease drugs are reducing exacerbations, slowing lung damage, and improving quality of life. With the increasing prevalence of Alpha 1 Lung Disease globally, there is a huge demand for advanced drugs and treatment options for better management of the condition.

The Global Alpha 1 Lung Disease Market is estimated to be valued at US$ 4.99 Bn in 2023 and is expected to exhibit a CAGR of 18.9% over the forecast period 2023-2030.

Key Takeaways
Key players operating in the Alpha 1 Lung Disease market are AstraZeneca, Boehringer Ingelheim, Roche , Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical, CSL Behring, Vertex Pharmaceuticals, Amgen, Sanofi, GlaxoSmithKline, Gilead Sciences , Eli Lilly, AbbVie, Johnson & Johnson, Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals.

The growing prevalence of Alpha 1 Lung Disease globally is increasing the demand for advanced treatment options. As per estimates, around 100,000 people in the United States and millions across the world have Alpha 1 Lung Disease. The market players are focusing on R&D for developing gene therapy, which is expected to provide a definitive treatment over the current augmentation therapies.

The global expansion of key pharmaceutical companies in emerging markets will also support market growth during the forecast period. For instance, companies are focusing on partnerships and acquisitions in Asian markets to expand presence.

Market key trends
Gene therapy is one of the major trends gaining traction in the Alpha 1 Lung Disease market. It involves replacing the deficient gene with a healthy copy of the gene to ensure continuous production of AAT protein in the liver. Companies are investing heavily in developing innovative gene therapies. For example, Vertex Pharmaceuticals’ pipeline candidate VX-864 is an investigational AAT gene therapy for the treatment of Alpha 1 Lung Disease. Positive data from ongoing trials can transform the treatment landscape in the upcoming years.

Porter’s Analysis

Threat of new entrants: Due to high requirement of capital investment and stringent regulations, threat is low.

Bargaining power of buyers: Large players like hospitals have strong bargaining power due to bulk purchase.

Bargaining power of suppliers: Suppliers have moderate bargaining power due to presence of many suppliers and substitutes.

Threat of new substitutes: Threat is moderate as there are few approved treatment options currently and new entrants face high entry barriers.

Competitive rivalry: Intense as market is dominated by major global pharmaceutical companies investing heavily in R&D.

Geographical regions with highest market value

North America accounts for the largest share of the alpha 1 lung disease market currently, primarily due to developed healthcare infrastructure, rising awareness and high diagnosis rates. The United States contributes majority of the region’s market value.

Fastest growing geographical region

Asia Pacific region is poised to witness the highest growth during the forecast period owing to increasing healthcare expenditures, large patient pool, growing medical tourism and growing awareness about alpha 1 lung disease. Rising incidences due to changing lifestyle in developing countries like China and India will support the regional market growth.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it